TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Scinai Immunotherapeutics ( (SCNI) ) has shared an update.
Scinai Immunotherapeutics Ltd. announced the resignation of two board members, Prof. Avner Rotman and Dr. Morris Laster, effective December 31, 2025, as part of cost-cutting measures. Additionally, the company plans to replace its current accounting firm, PwC, with Ziv Haft to further reduce costs, pending shareholder approval.
Spark’s Take on SCNI Stock
According to Spark, TipRanks’ AI Analyst, SCNI is a Neutral.
Scinai Immunotherapeutics is undergoing a financial recovery but faces significant challenges such as negative cash flows and high debt levels. The stock shows neutral technical indicators, suggesting moderate market confidence. Its attractive valuation might appeal to value investors, but the absence of dividends and financial risks may deter more conservative investors.
To see Spark’s full report on SCNI stock, click here.
More about Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. operates in the biotechnology industry, focusing on immunotherapeutic products. The company is based in Jerusalem, Israel, and is involved in developing innovative solutions for immune-related conditions.
Average Trading Volume: 139,555
Technical Sentiment Signal: Sell
Current Market Cap: $934K
For a thorough assessment of SCNI stock, go to TipRanks’ Stock Analysis page.